Searched for: in-biosketch:true
person:gondat01
The Use of Biomarkers in the Risk Stratification of Cystic Neoplasms
Kaplan, Jeremy H; Gonda, Tamas A
Cyst fluid biomarkers may be used to identify pancreatic cyst subtypes. Biomarkers are selected based on their ability to accurately distinguish mucinous from nonmucinous cysts and to risk stratify cysts based on malignant potential. Biomarkers of interest include but are not limited to amylase, oncogenes, DNA analysis, and epigenetic markers. The introduction of next-generation sequencing and molecular panels has aided in improved diagnostic accuracy and risk stratification. This review presents the diagnostic performance of currently available biomarkers and proposes an algorithm to incorporate their use in the diagnosis of pancreatic cysts.
PMID: 30241643
ISSN: 1558-1950
CID: 3980862
Comparing EUS-Fine Needle Aspiration and EUS-Fine Needle Biopsy for Solid Lesions: A Multicenter, Randomized Trial
Nagula, Satish; Pourmand, Kamron; Aslanian, Harry; Bucobo, Juan Carlos; Gonda, Tamas; Gonzalez, Susana; Goodman, Adam; Gross, Seth A; Ho, Sammy; DiMaio, Christopher J; Kim, Michelle; Pais, Shireen; Poneros, John; Robbins, David; Schnoll-Sussman, Felice; Sethi, Amrita; Buscaglia, Jonathan M
BACKGROUND & AIMS: Endoscopic ultrasound (EUS) with fine needle aspiration (FNA) is the standard of care for tissue sampling of solid lesions adjacent to the GI tract. Fine needle biopsy (FNB) may provide higher diagnostic yield with fewer needle passes. The aim of this study was to assess the difference in diagnostic yield between FNA and FNB. METHODS: This is a multicenter, prospective randomized clinical trial from six large tertiary care centers. Patients referred for tissue sampling of solid lesions were randomized to either FNA or FNB of the target lesion. Demographics, size, location, number of needle passes, and final diagnosis were recorded. RESULTS: After enrollment, 135 patients were randomized to FNA (49.3%) and 139 patients were randomized to FNB (50.7%).The following lesions were sampled: mass (n=210; 76.6%), lymph nodes (n=46, 16.8%), submucosal tumors (n=18, 6.6%). Final diagnosis was malignancy (n=192, 70.1%), reactive lymphadenopathy (n=30, 11.0%), and spindle cell tumors (n=24, 8.8%). FNA had a diagnostic yield of 91.1% compared to 88.5% for FNB (p=0.48). There was no difference between FNA and FNB when stratified by the presence of on-site cytopathology or by type of lesion sampled A median of 1 needle pass was needed to obtain a diagnostic sample for both needles. CONCLUSION: FNA and FNB obtained a similar diagnostic yield with a comparable number of needle passes. Based on these results, there is no significant difference in the performance of FNA compared to FNB in the cytological diagnosis of solid lesions adjacent to the GI tract. (ClincalTrials.gov identifier: NCT01698190).
PMID: 28624647
ISSN: 1542-7714
CID: 2604112
ATP11B mediates platinum resistance in ovarian cancer
Moreno-Smith, Myrthala; Halder, J B; Meltzer, Paul S; Gonda, Tamas A; Mangala, Lingegowda S; Rupaimoole, Rajesha; Lu, Chunhua; Nagaraja, Archana S; Gharpure, Kshipra M; Kang, Yu; Rodriguez-Aguayo, Cristian; Vivas-Mejia, Pablo E; Zand, Behrouz; Schmandt, Rosemarie; Wang, Hua; Langley, Robert R; Jennings, Nicholas B; Ivan, Cristina; Coffin, Jeremy E; Armaiz, Guillermo N; Bottsford-Miller, Justin; Kim, Sang Bae; Halleck, Margaret S; Hendrix, Mary Jc; Bornman, William; Bar-Eli, Menashe; Lee, Ju-Seog; Siddik, Zahid H; Lopez-Berestein, Gabriel; Sood, Anil K
PMID: 29809169
ISSN: 1558-8238
CID: 4520882
A PROSPECTIVE VALIDATION OF THE FIRST ENDOSCOPIC MANAGEMENT ALGORITHM FOR GASTROINTESTINAL BLEEDING IN PATIENTS WITH CONTINUOUS-FLOW LEFT VENTRICULAR ASSIST DEVICES [Meeting Abstract]
Axelrad, Jordan; Pinsino, Alberto; Trinh, Pauline; Thanataveerat, Anusorn; Ramirez, Ivonne; Garcia-Carrasquillo, Reuben J.; Colombo, Paolo; Yuzefpolskaya, Melana; Gonda, Tamas A.
ISI:000434248200533
ISSN: 0016-5107
CID: 3182952
Limited usefulness of endoscopic evaluation in patients with continuous-flow left ventricular assist devices and gastrointestinal bleeding
Axelrad, Jordan E; Pinsino, Alberto; Trinh, Pauline N; Thanataveerat, Anusorn; Brooks, Christian; Demmer, Ryan T; Effner, Lisa; Parkis, Grant; Cagliostro, Barbara; Han, Jiho; Garan, A Reshad; Topkara, Veli; Takeda, Koji; Takayama, Hiroo; Naka, Yoshifumi; Ramirez, Ivonne; Garcia-Carrasquillo, Reuben; Colombo, Paolo C; Gonda, Tamas; Yuzefpolskaya, Melana
BACKGROUND:Gastrointestinal bleeding (GIB) is a frequent cause of re-admission in patients with continuous-flow left ventricular assist devices (CF-LVADs) and is associated with multiple endoscopic procedures and high resource utilization. Our aim was to determine the diagnostic and therapeutic yield of endoscopy and to develop a more cost-effective approach for the management of GIB in CF-LVAD recipients. METHODS:We retrospectively reviewed 428 patients implanted with a CF-LVAD between 2009 and 2016 at the Columbia University Medical Center and identified those hospitalized for GIB. Patients were categorized into upper GIB (UGIB), lower GIB (LGIB) and occult GIB (OGIB), based on clinical presentation. RESULTS:Eighty-seven CF-LVAD patients underwent a total of 164 GIBs, resulting in 239 endoscopies. Index presentation was consistent with UGIB in 30 (34.5%), LGIB in 19 (21.8%) and OGIB in 38 (43.7%) patients. On the first GIB, 147 endoscopies localized a bleeding source in 49 (30%), resulting in 24 (16.3%) endoscopic interventions. Of 45 lesions identified, arteriovenous malformations (AVMs) were the most common (22, 48.9%). A gastric or small bowel source (HR 2.8, p = 0.003) and an endoscopic intervention (HR 1.9, p = 0.04) predicted recurrent GIB. The proposed algorithm may reduce the number of endoscopic procedures by 45% and costs by 35%. CONCLUSIONS:Occult GIB is the most common presentation in CF-LVAD patients and carries the lowest diagnostic and therapeutic yield of endoscopy. Performing an intervention was among the strongest predictors of recurrent GIB. Our proposed algorithm may decrease the number of low-yield procedures and improve resource utilization.
PMID: 29402604
ISSN: 1557-3117
CID: 3177902
Predictors of Progression Among Low-Risk Intraductal Papillary Mucinous Neoplasms in a Multicenter Surveillance Cohort
Gausman, Valerie; Kandel, Pujan; Van Riet, Priscilla A; Moris, Maria; Kayal, Maia; Do, Catherine; Poneros, John M; Sethi, Amrita; Gress, Frank G; Schrope, Beth A; Luk, Lyndon; Hecht, Elizabeth; Jovani, Manol; Bruno, Marco J; Cahen, Djuna L; Wallace, Michael B; Gonda, Tamas A
OBJECTIVES/OBJECTIVE:Our aim was to identify baseline characteristics associated with disease progression and malignant transformation in low-risk suspected intraductal papillary mucinous neoplasms (IPMNs). METHODS:This is a retrospective cohort study of prospectively maintained databases of pancreatic cysts at 3 international, academic institutions. Five hundred fifty-nine adult patients with clinically suspected asymptomatic IPMN evaluated by radiologic studies or endoscopic ultrasound between 2003 and 2013 without worrisome features and under surveillance for 12 months or longer were included. We evaluated the relationship of baseline demographics and cyst features to disease progression (size increase, development of worrisome features, or high-grade dysplasia/cancer). RESULTS:After a median of 44 months follow-up, 269 (48%) patients experienced cyst size increase, 68 (12%) developed worrisome features, and 11 (2%) developed high-grade dysplasia/cancer. In multivariable Cox-regression analysis, no baseline characteristics were associated with size increase. An initial cyst size of 2 cm or greater, multifocality, history of prostate cancer, and smoking were the strongest predictors of development of new worrisome features. Univariable analysis found male sex, diabetes, and recent weight loss associated with development of high-grade dysplasia/cancer. CONCLUSIONS:Our study demonstrates that low-risk suspected IPMNs carry a small but clinically relevant risk of disease progression and provides data on baseline characteristics that may help in risk stratification.
PMID: 29521942
ISSN: 1536-4828
CID: 3027202
Role of Fluorescent In Situ Hybridization, Cholangioscopic Biopsies, and EUS-FNA in the Evaluation of Biliary Strictures
Brooks, Christian; Gausman, Valerie; Kokoy-Mondragon, Chanthel; Munot, Khushboo; Amin, Sunil P; Desai, Amit; Kipp, Claudine; Poneros, John; Sethi, Amrita; Gress, Frank G; Kahaleh, Michel; Murty, Vundavalli V; Sharaiha, Reem; Gonda, Tamas A
BACKGROUND AND AIMS/OBJECTIVE:Our goal was to compare the diagnostic accuracy of FISH in the detection of malignancy compared with other standard diagnostic modalities, including brush cytology and biopsy specimens over a 10-year period of prospective data collection. METHODS:We conducted a review of all consecutive biliary strictures evaluated between 2006 and 2016. Patients with a final pathologic diagnosis or conclusive follow-up were included. We evaluated the performance of FISH polysomy (CEP 3, 7, and 17) and 9p21 deletion as well as cholangioscopic biopsy (CBx) and EUS-FNA. Statistical analysis was performed with the Mann-Whitney U and Fisher's exact tests. RESULTS:Of 382 patients with indeterminate strictures, 281 met inclusion criteria. Forty-nine percent were malignant. Cytology, FISH polysomy, and FISH polysomy/9p21 showed a specificity of 99.3%. FISH polysomy/9p21 as a single modality was the most sensitive at 56% (p < 0.001). The sensitivity of FISH polysomy/9p21 and cytology was significantly higher than cytology alone at 63 versus 35% (p < 0.05). EUS-FNA for distal strictures and CBx for proximal strictures increased sensitivity from 33 to 93% (p < 0.001) and 48-76% (p = 0.05) in cytology-negative strictures. CONCLUSIONS:The high specificity of FISH polysomy/9p21 suggests that a positive result is sufficient for diagnosing malignancy in indeterminate strictures. The significantly higher sensitivity of FISH polysomy/9p21 compared to cytology supports the use of FISH in all non-diagnostic cases. Although both EUS-FNA and CBx were complimentary, our results suggest that distal strictures should be evaluated by EUS initially. Proximal strictures may be evaluated by FISH first and then by CBx if inconclusive.
PMID: 29353443
ISSN: 1573-2568
CID: 4520872
A phase II study of chemotherapy and immune checkpoint blockade with pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma. [Meeting Abstract]
Oberstein, Paul Eliezer; Schrope, Beth; Gonda, Tamas; Sethi, Amrita; Han, Arnold; Schwartz, Gary K.; Shah, Manish A.
ISI:000436174100189
ISSN: 0732-183x
CID: 3564642
Phase II open-label, single-center study evaluating safety and efficacy of pembrolizumab following induction with the hypomethylating agent azacitidine in patients with advanced pancreatic cancer after failure of first-line therapy. [Meeting Abstract]
Safyan, Rachael A.; Gonda, Tamas; Tycko, Benjamin; Chabot, John A.; Manji, Gulam Abbas; Schwartz, Gary K.; Oberstein, Paul Eliezer
ISI:000436174100514
ISSN: 0732-183x
CID: 3564662
Fully-covered metal stents with endoscopic suturing vs. partially-covered metal stents for benign upper gastrointestinal diseases: a comparative study
Ngamruengphong, Saowanee; Sharaiha, Reem; Sethi, Amrita; Siddiqui, Ali; DiMaio, Christopher J; Gonzalez, Susana; Rogart, Jason; Jagroop, Sophia; Widmer, Jessica; Im, Jennifer; Hasan, Raza Abbas; Laique, Sobia; Gonda, Tamas; Poneros, John; Desai, Amit; Wong, Katherine; Villgran, Vipin; Brewer Gutierrez, Olaya; Bukhari, Majidah; Chen, Yen-I; Hernaez, Ruben; Hanada, Yuri; Sanaei, Omid; Agarwal, Amol; Kalloo, Anthony N; Kumbhari, Vivek; Singh, Vikesh; Khashab, Mouen A
Background and study aims /UNASSIGNED:Self-expandable metallic stents (SEMS) have been increasingly used in benign conditions (e. g. strictures, fistulas, leaks, and perforations). Fully covered SEMS (FSEMS) were introduced to avoid undesirable consequences of partially covered SEMS (PSEMS), but come with higher risk of stent migration. Endoscopic suturing (ES) for stent fixation has been shown to reduce migration of FSEMS. Our aim was to compare the outcomes of FSEMS with ES (FS/ES) versus PSEMS in patients with benign upper gastrointestinal conditions. Patients and methods /UNASSIGNED:We retrospectively identified all patients who underwent stent placement for benign gastrointestinal conditions at seven US tertiary-care centers. Patients were divided into two groups: FSEMS with ES (FS/ES group) and PSEMS (PSEMS group). Clinical outcomes between the two groups were compared. Results /UNASSIGNED: = 0.005. Conclusions /UNASSIGNED:The proportion of stent migration of FS/ES and PSEMS are similar. Rates of other stent-related AEs were higher in the PSEMS group. PSEMS was associated with tissue ingrowth or overgrowth leading to difficult stent removal, and secondary stricture formation. Thus, FSEMS with ES for stent fixation may be the preferred modality over PSEMS for the treatment of benign upper gastrointestinal conditions.
PMID: 29404384
ISSN: 2364-3722
CID: 3411692